Online inquiry

IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10763MR)

This product GTTS-WQ10763MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGFR4 gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001291980.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2264
UniProt ID P22455
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10763MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9991MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KD-247
GTTS-WQ10559MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ7056MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ4288MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ10903MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ4207MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ2536MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ4333MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIW-8405
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW